StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Monday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
NAVB opened at $0.00 on Monday. The company has a market cap of $100,084.00, a price-to-earnings ratio of -0.02 and a beta of 1.49. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.15.
Navidea Biopharmaceuticals Company Profile
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- The Most Important Warren Buffett Stock for Investors: His Own
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- How to Invest in Insurance Companies: A Guide
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Dividend Capture Strategy: What You Need to Know
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.